ADL
KERX

Asset Dedication LLC’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Asset Dedication LLC’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,250
Closed -$6K – 698
2015
Q4 		$6K Buy
+1,250
New +$5.94K ﹤0.01% 452

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Asset Dedication LLC's KERX Position: Q1 2016 in Review

Asset Dedication LLC sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2016, closing a stake of 1,250 shares — an estimated $6K sold.

Asset Dedication LLC first reported a position in KERX in Q4 2015 and held it in 1 quarter. The position peaked at $6K in Q4 2015. 130 funds tracked by Wall St. Rank hold KERX as of Q1 2016.

  • Asset Dedication LLC reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Asset Dedication LLC sold 1,250 Keryx Biopharmaceuticals Inc shares in Q1 2016, an estimated $6K.
  • Asset Dedication LLC first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 1 quarter.
  • Asset Dedication LLC's Keryx Biopharmaceuticals Inc position peaked at $6K in Q4 2015.
  • 130 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2016.

Based on Asset Dedication LLC's 13F filing for Q1 2016, filed 27 Apr 2016.